Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Atidarsagene Autotemcel→

Atidarsagene Autotemcel Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
Not available
Drug class
Autologous CD34+ haematopoietic stem-cell gene therapylentiviral ARSA gene addition product
Mechanism of action
Autologous CD34+ cells are transduced ex vivo with a lentiviral vector encoding functional human arylsulfatase A (ARSA), then reinfused after conditioning. Transduced cells engraft and provide ARSA-expressing progeny, including myeloid-lineage cells, to restore enzyme activity and reduce sulfatide accumulation in the nervous system.
Indications / reported uses
  • Treatment of selected presymptomatic late-infantile or early-juvenile and early-symptomatic early-juvenile metachromatic leukodystrophy (MLD) caused by biallelic ARSA mutations and deficient ARSA activity; eligibility depends on clinical stage and preserved function under the applicable product label

Sources: EMA EPAR — Libmeldy · US FDA — LENMELDY product page and indication · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Atidarsagene Autotemcel Environmental Risk Assessment (ERA) (the Atidarsagene Autotemcel ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.